Danielle Griffin

Title: The Innovative Contributions of Danielle Griffin

Introduction

Danielle Griffin is a prominent inventor based in Canal Winchester, OH (US). She has made significant strides in the field of gene therapy, particularly in the treatment of muscular dystrophy. Her work is characterized by a commitment to advancing medical science and improving patient outcomes.

Latest Patents

Danielle Griffin holds a patent for her innovative work titled "Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy." This patent describes methods for treating muscular dystrophy through the administration of a recombinant AAV vector, specifically AAVrh74.tMCK.hSGCA. The methods involve a systemic route of administration at a dose ranging from about 1.0×10^vg/kg to about 5.0×10^vg/kg. The patent further details techniques for expressing the alpha-sarcoglycan gene in cells or subjects, decreasing serum CK levels, and increasing alpha-sarcoglycan positive fibers in muscle tissue.

Career Highlights

Danielle Griffin is affiliated with the Research Institute at Nationwide Children's Hospital, where she continues to contribute to groundbreaking research. Her dedication to her work has positioned her as a key figure in the field of gene therapy.

Collaborations

Danielle collaborates with esteemed colleagues, including Louise Rodino-Klapac and Jerry R Mendell. These partnerships enhance her research efforts and contribute to the advancement of therapeutic strategies for muscular dystrophy.

Conclusion

Danielle Griffin's innovative work in gene therapy exemplifies her commitment to improving the lives of individuals affected by muscular dystrophy. Her contributions through her patent and collaborations highlight the importance of research in developing effective treatments.